Nisa Investment Advisors LLC Raises Position in Becton Dickinson and Co (BDX)

Nisa Investment Advisors LLC increased its position in Becton Dickinson and Co (NYSE:BDX) by 1.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 101,222 shares of the medical instruments supplier’s stock after buying an additional 1,800 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Becton Dickinson and were worth $25,278,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Standard Life Aberdeen plc boosted its holdings in shares of Becton Dickinson and by 2.5% during the 3rd quarter. Standard Life Aberdeen plc now owns 129,845 shares of the medical instruments supplier’s stock valued at $33,890,000 after buying an additional 3,134 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Becton Dickinson and during the 3rd quarter valued at $453,000. AQR Capital Management LLC boosted its holdings in shares of Becton Dickinson and by 36.9% during the 3rd quarter. AQR Capital Management LLC now owns 143,712 shares of the medical instruments supplier’s stock valued at $37,509,000 after buying an additional 38,709 shares in the last quarter. Kentucky Retirement Systems bought a new stake in shares of Becton Dickinson and during the 3rd quarter valued at $1,771,000. Finally, Teachers Advisors LLC boosted its holdings in shares of Becton Dickinson and by 0.7% during the 3rd quarter. Teachers Advisors LLC now owns 488,441 shares of the medical instruments supplier’s stock valued at $127,483,000 after buying an additional 3,366 shares in the last quarter. 84.87% of the stock is currently owned by institutional investors.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the transaction, the chief executive officer now owns 227,250 shares of the company’s stock, valued at approximately $56,903,400. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ribo Alberto Mas sold 4,808 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $1,226,184.24. Following the completion of the transaction, the executive vice president now directly owns 22,476 shares of the company’s stock, valued at approximately $5,732,054.28. The disclosure for this sale can be found here. In the last three months, insiders sold 29,684 shares of company stock valued at $7,518,574. 0.12% of the stock is owned by insiders.

BDX opened at $227.89 on Friday. The company has a quick ratio of 0.62, a current ratio of 0.97 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $61.32 billion, a PE ratio of 20.70, a P/E/G ratio of 1.74 and a beta of 1.21. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business had revenue of $4.16 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the previous year, the firm earned $2.48 EPS. Becton Dickinson and’s revenue was up 35.1% on a year-over-year basis. Sell-side analysts forecast that Becton Dickinson and Co will post 12.08 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date was Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.

BDX has been the subject of several recent analyst reports. Morgan Stanley lowered their price target on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 2nd. Raymond James lowered their price target on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research report on Tuesday, March 19th. Citigroup lowered their price target on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research report on Wednesday, January 2nd. TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Finally, Zacks Investment Research lowered Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $256.25.

TRADEMARK VIOLATION WARNING: This news story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2019/04/19/nisa-investment-advisors-llc-raises-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Growth and Income Funds

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.